大肠杆菌无痕重组的策略与应用

Red同源重组技术发展迅速,已经广泛应用于大肠杆菌基因的敲除、插入与替换。与传统的DNA有痕重组技术相比,基于Red重组原理的DNA无痕重组技术,能够更为精确、快速、高效地修饰大肠杆菌基因组中的目标基因,且在基因组中不残留任何外源片段,因此不会影响后续的基因操作与基因表达。从Red同源重组的原理出发,简要综述了近年来在大肠杆菌中广泛使用的无痕重组技术的原理及操作策略,并对比分析了各种方法的优势与不足;同时,还介绍了DNA无痕重组技术在大肠杆菌基因修饰中的应用情况。     

噬菌体重组酶介导的DNA同源重组工程

来源于噬菌体的遗传操作工具在基因工程中具有非常重要的地位,例如位点特异性重组酶、柯斯质粒DNA文库及同源重组酶等。其中,来源于lambda噬菌体的同源重组酶Redα/Redβ和来源于Rac原噬菌体的同源重组酶RecE/RecT能够高效地介导35–50 bp短同源臂之间的重组。基于噬菌体同源重组酶Redα/Redβ和RecE/RecT开发的DNA同源重组工程（Recombineering）能够对靶标DNA分子进行快速、精准、高效的修饰,不受限制性内切酶识别位点和DNA分子大小限制,已发展成为一种新型的基因工程技术。本文主要综述了噬菌体同源重组酶及其作用机制、在大肠杆菌及其他细菌中的应用和开发,以及在微生物次级代谢产物的挖掘、动植物转基因、病毒基因组克隆和修饰等方面的应用。原位激活沉默基因簇需要宿主特异性的DNA同源重组工程进行启动子和调控元件的修饰;异源表达次级代谢产物的首要步骤一般是通过RecET直接克隆大的DNA片段;动植物转基因复杂载体的构建效率在有了Red同源重组系统以后有了革命性的发展;RecET直接克隆和Red同源重组介导的感染性克隆构建和修饰方法,不仅有利于病毒基因组功能研究,同时也为载体疫苗开发提供了最优方案。     

重组工程及其应用

随着功能基因组研究的需要 ,新近建立起一项新型高效的基于体内同源重组的遗传工程技术———重组工程技术。重组工程可定义为 :基于噬菌体短同源序列重组功能的遗传工程 ,或者基于同源重组的遗传工程。λ噬菌体Red系统完全不同于传统的依赖RecA的大肠杆菌重组系统 ,特点是使用长度仅为 <5 0个碱基的同源臂高效率地催化体内同源重组反应。体内重组过程不再需要预先构建含有同源序列的质粒或噬菌体的中间产物 ,只需要简单在体外合成寡核苷酸同源序列 ,或者用PCR方法合成线性打靶序列。重组反应不依赖大肠杆菌RecA系统 ,不需要限制性内切核酸酶和连接酶 ,不需要复杂的体外重组操作 ,可在大肠杆菌体内对染色体DNA、对BAC和PAC质粒或普通质粒载体进行精确的修饰 ,包括真核或原核细胞基因组DNA的基因敲除、基因敲入、基因克隆和各种突变体的引入。由于该技术具有高效率、简单性和应用的广泛性等独特优点 ,将来完全有可能取代传统的遗传工程技术。主要介绍了λ噬菌体Red重组酶系统及重组工程在功能基因组研究方面的应用与进展     

Red重组系统用于大肠杆菌基因修饰的研究进展

Red重组作为一种新的重组系统已经被广泛用于大肠杆菌的基因敲除、基因替换。与传统的Rec重组相比,Red重组具有同源臂短,重组效率高等优点。本文分别详细介绍了Red重组系统中Exo、Beta、Gam三种蛋白质的功能,Red重组系统运用在大肠杆菌基因敲除中的三种质粒及其功能,同时概括了Red重组的技术要点及技术难点,分析了文献报道的阿拉伯糖诱导浓度和诱导时间、转化后的复苏温度及时间、引物同源臂长度对于重组率的影响,总结出了Red重组的最佳条件。     

利用Red重组系统敲除大肠杆菌 O157:H7的waaL 基因

目的:利用λ噬菌体Red重组系统敲除大肠杆菌O157:H7的waaL基因。方法:以pKD4为模板扩增出与waaL基因上下游同源的、含有卡那霉素抗性基因的PCR产物。然后电击转化到大肠杆菌 O157:H7 中,利用Red重组系统,通过卡那霉素抗性基因两侧的waaL基因序列在体内与waaL基因发生同源重组,置换了 O157:H7 基因组中的waaL基因。并进一步利用卡那霉素抗性基因两侧的FRT位点,通过FLP位点专一性重组将卡那霉素抗性基因敲除。结果:成功构建了敲除waaL基因且不带卡那霉素抗性基因的菌株。     

Red重组系统用于大肠杆菌基因修饰研究进展

Red重组作为一种新的重组系统已经被广泛用于大肠杆菌的基因敲除、基因替换.与传统的Rec重组相比,Red重组具有同源臂短,重组效率高等优点.分别详细介绍了Red重组系统中Exo、Beta、Gam 3种蛋白质的功能,Red重组系统运用于大肠杆菌基因敲除的3种质粒及其功能,同时概括了Red重组的技术要点及技术难点,分析了文献报道的阿拉伯糖诱导浓度和诱导时间、转化后的复苏温度及时间、引物同源臂长度对于重组率的影响,总结出了Red重组的最佳条件.     

Red同源重组技术研究进展

伴随着分子生物学的发展,一种基于λ噬菌体Red重组酶的同源重组系统已应用于大肠杆菌基因工程研究。Red重组系统由三种蛋白组成:Exo蛋白是一种核酸外切酶,结合在双链DNA的末端,从5′端向3′端降解DNA,产生3′突出端;Beta蛋白结合在单链DNA上,介导互补单链DNA退火;Gam蛋白可与RecBCD酶结合,抑制其降解外源DNA的活性。Red同源重组技术具有同源序列短(40～60bp)、重组效率高的特点。这种技术可在DNA靶标分子的任意位点进行基因敲除、敲入、点突变等操作,无需使用限制性内切酶和连接酶。此外,这种新型重组技术可直接将目的基因克隆于载体上,目的基因既可来源于细菌人工染色体也可是基因组DNA。Red同源重组技术使难度较大的基因工程实验顺利进行,大大推动功能基因组研究的发展。     

Red/ET同源重组技术及其在微生物基因组挖掘中的应用进展

Red/ET同源重组技术(Red/ET recombineering)是由来源于大肠杆菌λ噬菌体的蛋白对Redα/Redβ或来源于Rac原噬菌体的蛋白对Rec E/Rec T所介导的基于短同源臂(40–50 bp)的同源重组技术,能对宿主DNA序列进行快速、高效、精确的修饰和操作。本文主要综述了2010年以来Red/ET同源重组技术在大肠杆菌及其他细菌中的研究进展,同时简要介绍了该技术在微生物基因组挖掘,尤其是在微生物基因簇的异源表达领域的应用进展。     

一种快速、精确构建大肠杆菌组氨酸营养缺陷型的方法

将表达Red体内重组蛋白的质粒pKD46转化大肠杆菌：DH5α,用5′端与组氨酸基因同源,3′端与卡那霉素抗性基因同源的引物获得具有卡那霉素抗性基因的PCR产物,然后电击转化DH5α,在λRed重组系统的帮助下,通过卡那霉素抗性基因两侧的组氨酸基因序列在体内与大肠杆菌染色体上的组氨酸基因发生同源重组,置换了DH5α组氨酸操纵元中的hisDCB基因,最后利用卡那霉素抗性基因两端的FRT位点,通过FTP位点专一性重组将卡那霉素抗性基因去除,最终获得了不具抗性的大肠杆菌组氨酸营养缺陷型菌株。为在大肠杆菌及其他菌株中快速、精确的构建营养缺陷型菌株提供了有益的参考。     

一种由寡核苷酸介导的大肠杆菌ftsZ基因无痕敲除的方法

现阶段,适用于大肠杆菌的无痕敲除方法普遍存在周期较长、操作步骤复杂等问题。为了进一步改进和优化无痕敲除技术,采用单链寡核苷酸介导的Red同源重组系统（single strand oligonucleotide-mediated recombineering,SSOR）,通过两步连续的同源重组,敲除了一种编码类似微管蛋白的GTP酶的ftsZ基因。该方法可快速高效无痕的敲除目的基因,为大肠杆菌基因组改造提供了有效方法,另外,ftsZ基因缺失株的获得也为研究ftsZ基因功能创造了条件。     

一种新的基于Red重组及I-Sec I体内切割的大肠杆菌基因组无痕删减方法

目前常用的基因修饰方法是在Red同源重组介导下,电转线性PCR片段替换染色体上指定序列。因PCR过程错误掺入,该方法常常会在同源序列部位产生一些突变。为了避免此类突变,我们建立了一种新的无痕删除方法。首先将含有抗性标记(两侧带有I-Sec I识别位点)的线性DNA电转到Red重组感受态细胞内,用抗性基因替换基因组上指定序列;然后,将携带融合同源臂(两侧带有I-Sec I位点)的供体质粒导入上述细胞,诱导表达I-Sec I内切酶切割供体质粒释放同源片段,同时切除染色体上抗性基因产生双链断裂,通过分子间同源重组实现无痕删除。我们应用该方法连续删除了大肠杆菌DH1基因组上11个非必需区,使基因组减小10.59%。PCR测序证明所有删减区域同源臂未发生突变,基因组重测序证明指定区域被删除。删减菌的生长变化不大,但耐酸能力有所改变,并对番茄红素合成有不同影响。     

Intact recombineering of highly repetitive DNA requires reduced induction of recombination enzymes and improved host viability

Recombineering technology permits flexible engineering of large DNA in Escherichia coli without dependence on suitably placed restriction sites. However, recombineering is limited for modifying highly repetitive DNA because of its potential to trigger instability by uncontrolled self-recombination of the repeats. In this study, induction of the recombineering enzymes and growth condition of the host are optimized to demonstrate intact modification of bacterial artificial chromosomes (BACs) containing long arrays of centromeric alpha satellite repeats. This optimized recombineering protocol may be useful for manipulation of other biologically important repetitive DNAs, including trinucleotide repeat expansions and homologous gene families, to facilitate their functional studies.     

Developing live Shigella vaccines using lambda Red recombineering

Live attenuated Shigella vaccines have shown promise in inducing protective immune responses in human clinical trials and as carriers of heterologous antigens from other mucosal pathogens. In the past, construction of Shigella vaccine strains relied on classical allelic exchange systems to genetically engineer the bacterial genome. These systems require extensive in vitro engineering of long homologous sequences to create recombinant replication-defective plasmids or phage. Alternatively, the lambda red recombination system from bacteriophage facilitates recombination with as little as 40 bp of homologous DNA. The process, referred to as recombineering, typically uses an inducible lambda red operon on a temperature-sensitive plasmid and optimal transformation conditions to integrate linear antibiotic resistance cassettes flanked by homologous sequences into a bacterial genome. Recent advances in recombineering have enabled modification of genomic DNA from bacterial pathogens including Salmonella, Yersinia, enteropathogenic Escherichia coli, or enterohemorrhagic E. coli and Shigella. These advances in recombineering have been used to systematically delete virulence-associated genes from Shigella, creating a number of isogenic strains from multiple Shigella serotypes. These strains have been characterized for attenuation using both in vivo and in vitro assays. Based on this data, prototypic Shigella vaccine strains containing multiple deletions in virulence-associated genes have been generated.     

Fluorescent protein engineering by in vivo site-directed mutagenesis

In vivo site-directed mutagenesis by single-stranded deoxyribonucleic acid recombineering is a facile method to change the color of fluorescent proteins (FPs) without cloning. Two different starting alleles of GFP were targeted for mutagenesis: gfpmut3* residing in the Escherichia coli genome and egfp carried by a bacterial/mammalian dual expression lentiviral plasmid vector. Fluorescent protein spectra were shifted by subtle modification of the chromophore region and residues interacting with the chromophore of the FP. Eight different FPs (Violeta, Azure, Aqua, Mar, Celeste, Amarillo, Mostaza, and Bronze) were isolated and shown to be useful in multicolor imaging and flow cytometry of bacteria and transgenic human stem cells. To make in vivo site-directed mutagenesis more efficient, the recombineering method was optimized using the fluorescence change as a sensitive quantitative assay for recombination. A set of rules to simplify mutant isolation by recombineering is provided.     

Efficient point mutagenesis in mycobacteria using single-stranded DNA recombineering: characterization of antimycobacterial drug targets

Construction of genetically isogenic strains of mycobacteria is complicated by poor recombination rates and the lack of generalized transducing phages for Mycobacterium tuberculosis . We report here a powerful method for introducing single point mutations into mycobacterial genomes using oligonucleotide-derived single-stranded DNA recombineering and mycobacteriophage-encoded proteins. Phage Che9c gp61-mediated recombination is sufficiently efficient that single base changes can be introduced without requirement for direct selection, with isogenic mutant strains identified simply by PCR. Efficient recombination requires only short (50 nucleotide) oligonucleotides, but there is an unusually strong strand bias and an oligonucleotide targeting lagging strand DNA synthesis can recombine more than 10 000-fold efficiently than its complementary oligonucleotide. This ssDNA recombineering provides a simple assay for comparing the activities of related phage recombinases, and we find that both Escherichia coli RecET and phage λ Red recombination proteins function inefficiently in mycobacteria, illustrating the utility of developing recombineering in new bacterial systems using host-specific bacteriophage recombinases. ssDNA mycobacterial recombineering provides a simple approach to characterizing antimycobacterial drug targets, and we have constructed and characterized single point mutations that confer resistance to isoniazid, rifampicin, ofloxacin and streptomycin.     

High efficiency recombineering in lactic acid bacteria

The ability to efficiently generate targeted point mutations in the chromosome without the need for antibiotics, or other means of selection, is a powerful strategy for genome engineering. Although oligonucleotide-mediated recombineering (ssDNA recombineering) has been utilized in Escherichia coli for over a decade, the successful adaptation of ssDNA recombineering to Gram-positive bacteria has not been reported. Here we describe the development and application of ssDNA recombineering in lactic acid bacteria. Mutations were incorporated in the chromosome of Lactobacillus reuteri and Lactococcus lactis without selection at frequencies ranging between 0.4% and 19%. Whole genome sequence analysis showed that ssDNA recombineering is specific and not hypermutagenic. To highlight the utility of ssDNA recombineering we reduced the intrinsic vancomymycin resistance of L. reuteri >100-fold. By creating a single amino acid change in the d-Ala-d-Ala ligase enzyme we reduced the minimum inhibitory concentration for vancomycin from >256 to 1.5 µg/ml, well below the clinically relevant minimum inhibitory concentration. Recombineering thus allows high efficiency mutagenesis in lactobacilli and lactococci, and may be used to further enhance beneficial properties and safety of strains used in medicine and industry. We expect that this work will serve as a blueprint for the adaptation of ssDNA recombineering to other Gram-positive bacteria.     

pBR322-Red在大肠杆菌lac操纵子基因敲除和敲入中的应用

pBR322-Red是一种新型重组工程系统,它携带了λ-噬菌体Red重组酶基因和一系列调控元件.对pBR322-Red最优重组条件进行探索后应用该质粒提供的体内同源重组功能,在菌株W3110体内,对染色体上的lac操纵子进行了基因修饰,包括:①运用kan/sacB选择反选择方法和重叠引物方法敲除了阻遏基因lacⅠ,②运用kan/sacB选择反选择方法和线性双链DNA介导的DNA重组方法将报告基因lacZ敲入lacA和lacY的位置,并且首次测定了报告基因lacZ在这三个结构基因位置的组成性表达情况.结果表明运用不同的重组策略,pBR322-Red系统都能方便有效地对大肠杆菌W3110染色体进行基因敲除和敲入修饰.     

Recombineering in Mycobacterium tuberculosis

Genetic dissection of M. tuberculosis is complicated by its slow growth and its high rate of illegitimate recombination relative to homologous DNA exchange. We report here the development of a facile allelic exchange system by identification and expression of mycobacteriophage-encoded recombination proteins, adapting a strategy developed previously for recombineering in Escherichia coli. Identifiable recombination proteins are rare in mycobacteriophages, and only 1 of 30 genomically characterized mycobacteriophages (Che9c) encodes homologs of both RecE and RecT. Expression and biochemical characterization show that Che9c gp60 and gp61 encode exonuclease and DNA-binding activities, respectively, and expression of these proteins substantially elevates recombination facilitating allelic exchange in both M. smegmatis and M. tuberculosis. Mycobacterial recombineering thus provides a simple approach for the construction of gene replacement mutants in both slow- and fast-growing mycobacteria.